Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 November 2021Website:
http://www.calidibio.comNext earnings report:
14 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:47:31 GMTDividend
Analysts recommendations
Institutional Ownership
CLDI Latest News
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024, and reviewed recent business highlights.
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 2,050,000 shares of the Company's common stock at a price of $1.00 per share of common stock in a registered direct offering.
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants — ticker symbol CLDI WS — of Calidi Biotherapeutics, Inc. (the “Company”), each whole warrant exercisable for 1/10th of a share of common stock at an exercise price of $115.00 per whole share of common stock, from the NYSE American. Trading in the Company's warrants will be suspended immediately. Trading in the Company's common stock — ticker symbol CLDI — will continue on the NYSE American.
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024, and reviewed recent business highlights.
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi to Effect Reverse Stock Split.
SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces Exercise of Warrants for $1.9 Million Gross Proceeds.
RedChip Companies is set to broadcast interviews with Calidi Biotherapeutics Inc. (NYSE American:CLDI) and Unusual Machines Inc. (NYSE American:UMAC) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, May 18, at 7 p.m. ET.
What type of business is Calidi Biotherapeutics?
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
What sector is Calidi Biotherapeutics in?
Calidi Biotherapeutics is in the Healthcare sector
What industry is Calidi Biotherapeutics in?
Calidi Biotherapeutics is in the Biotechnology industry
What country is Calidi Biotherapeutics from?
Calidi Biotherapeutics is headquartered in United States
When did Calidi Biotherapeutics go public?
Calidi Biotherapeutics initial public offering (IPO) was on 01 November 2021
What is Calidi Biotherapeutics website?
https://www.calidibio.com
Is Calidi Biotherapeutics in the S&P 500?
No, Calidi Biotherapeutics is not included in the S&P 500 index
Is Calidi Biotherapeutics in the NASDAQ 100?
No, Calidi Biotherapeutics is not included in the NASDAQ 100 index
Is Calidi Biotherapeutics in the Dow Jones?
No, Calidi Biotherapeutics is not included in the Dow Jones index
When was Calidi Biotherapeutics the previous earnings report?
No data
When does Calidi Biotherapeutics earnings report?
The next expected earnings date for Calidi Biotherapeutics is 14 March 2025